[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arteriosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arteriosclerosis":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,61,99,128,154,182,206,235,264,291],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":43,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100612800","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-rms-system-in-subjects-with-coronary-artery-lesions-100612800",false,"NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)","ALL","18 Years","80 Years",{"count":21,"type":22},1859,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Angina Pectoris",[44,45,46,47],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","RECRUITING","2026-06-15",{"date":51,"type":52},"2026-06-17","ACTUAL",{"date":54,"type":52},"2026-06-11",{"date":56,"type":22},"2033-06",{"name":58,"class":59},"Teleflex","INDUSTRY",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":23,"phases":72,"briefSummary":73,"conditions":74,"keywords":80,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":60},"100562453","changes-in-plaque-characteristics-after-short-term-statin-therapy-as-assessed-with-coronary-ct-100562453","NCT06603363","Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT","INTENSE","Inclusion Criteria:\n\n* patients referred for coronary computed tomography angiography (CTA)\n* females aged 45-75 years and males aged 40-75 years\n* presence of at least mild coronary atherosclerosis (luminal stenosis \\>25%, with at least one partially calcified or non-calcified plaque)\n* statin-naive patients\n* ability to understand and provide written informed consent\n* FFR-CT value ≥0.75, indicating the absence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* contraindications to coronary CTA\n* current or prior treatment with statins or other lipid-lowering agents (e.g., ezetimibe)\n* age below 45 years in females or below 40 years in males\n* age above 75 years in both sexes\n* pregnancy or breastfeeding\n* type 1 or type 2 diabetes mellitus\n* history of coronary stent implantation or coronary artery bypass grafting\n* history of myocardial infarction\n* ≥70% luminal stenosis in the proximal left anterior descending artery (LAD), or ≥50% stenosis in the left main (LM) coronary artery\n* FFR-CT value \\\u003C0.75 in any coronary artery\n* elevated serum alanine aminotransferase (ALT) levels (\\>3× the upper limit of normal)\n* elevated serum creatine kinase (CK) levels (\\>3× the upper limit of normal)\n* LDL cholesterol level \\>5 mmol\u002FL\n* renal failure or significantly impaired renal function (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* ongoing oncological treatment\n* active liver disease\n* known hypersensitivity to any excipients of the investigational product\n* concomitant treatment with the combination of sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir\n* concomitant treatment with cyclosporine\n* women of childbearing potential not using adequate contraception\n* presence of myopathy","45 Years","75 Years",{"count":71,"type":22},140,[25],"INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for rosuvastatin) among statin-naive patients referred to coronary CT angiography due to stable chest pain, followed for 24 months by using a photon-counting detector CT (PCD-CT).\n\nINTENSE Trial aims 1) to assess the effect of short-term intensified statin therapy on coronary anatomy and physiology using PCD-CT and 2) to determine the impact of short-term, intensified statin therapy on coronary plaque morphology and hemodynamics to identify statin responder and non-responder patients in addition to testing the hypothesis of \"plaque memory\" after the 24-month follow-up period.",[39,75,76,77,78,29,30,31,33,79],"Atherosclerotic Plaque","Coronary Computed Tomography Angiography","Statin Therapy","Multidetector Computed Tomography","Hyperlipidemia",[81,82,83,84,85,86,87,88],"coronary artery disease","stable chest pain","intermediate pretest probability","explanatory randomised controlled trial","coronary computed tomography angiography","photon-counting detector CT","atherosclerotic plaque","statin therapy","2026-05-08",{"date":91,"type":52},"2026-05-13",{"date":93,"type":52},"2025-05-28",{"date":95,"type":22},"2028-12-15",{"name":97,"class":98},"Prof. Maurovich-Horvat Pál","OTHER",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":109,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":5},"100486901","durg-coated-balloon-angioplasty-in-infrapopliteal-lesions-100486901","NCT05620095","Durg Coated Balloon Angioplasty in Infrapopliteal Lesions","Multicenter Registry for pAclitaxel- Coated Balloon angioplasTy in Infrapopliteal Arterial Lesions (the ACT Study)","Act","Inclusion Criteria:\n\n1. Rutherford grade 4-6.\n2. Patients who understand the purpose of this study, volunteer to participate in the experiment, sign informed consent and are willing to follow up.\n3. Single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the infrapopliteal arteries \\>20 mm. Lesions should not extend beyond the ankle joint.\n4. Successful wire crossing of the lesion. After the pre-dilation of the ordinary balloon, the angiography showed that there was continuous blood flow.\n5. At least one of the infrapopliteal arteries received a drug-coated balloon.\n6. For patients with aortoiliac artery disease and femoral-popliteal artery disease, after intravascular reconstruction, blood flow can be recanalized, and there is no residual stenosis of more than 50%.\n7. In patients with lower extremity arterial thrombosis, after mechanical thrombectomy, percutaneous catheter thrombolysis, and thrombus removal, patients receiving blew the knee arterial drug balloon intervention.\n8. Patients who have received DCB intervention for both lower limbs can be enrolled in the group according to the intracavitary treatment time.\n9. Life expectancy\\> 24 months.\n\nExclusion Criteria:\n\n1. Blood flow was not successfully reestablished.\n2. Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within 3 months before enrollment.\n3. Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc.\n4. Patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months.\n5. Pregnant and lactating women.\n6. Patients with Berg's disease.\n7. Patients requiring major amputation based on preoperative evaluation of limb infection or severe ischemia",{"count":108,"type":22},1000,"1 Year","OBSERVATIONAL","This study is a multicenter observational study designed to evaluate the the effectiveness and safety of drug-coated balloon (DCB) angioplasty for below the knee arterial lesions in patients critical with Limb Threatening Ischemia (CLTI).",[31,113,114],"Peripheral Artery Disease","Chronic Limb Threatening Ischemia",[116,117,118],"Drug-coated Balloon","Angioplasty","Below the knee","2026-03-20",{"date":121,"type":52},"2026-03-25",{"date":123,"type":52},"2020-12-01",{"date":125,"type":22},"2026-11-01",{"name":127,"class":98},"Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100614975","a-prospective-multicenter-randomized-controlled-trial-to-investigate-the-value-of-coronary-ct-angiography-in-the-understanding-and-management-of-coronary-calcium-the-optimal-trial-100614975","NCT07286578","A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)","A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium","Inclusion Criteria:\n\n* The subject must be at least 18 years of age and younger than 85 years old\n* Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia (ischemia in the absence of chest pain or other anginal equivalents), unstable angina, or acute myocardial infarction) suitable for PCI. Patients with a clinical indication for revascularization presenting with stable coronary artery disease or stabilized acute coronary syndrome defined as follows unstable angina (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC), patients with NSTEMI without high-risk features such as recurrence of chest pain, ST-segment depression\\>1mm in ≥6 leads plus STsegment elevation in aVR, life-threatening arrhythmias, mechanical complications of MI, resuscitated cardiac arrest, GRACE risk score\\>140.\n* All target vessels must have reference vessel diameter (visually assessed by CCTA) ≥ 2.5 mm\n* Subject must provide written informed consent before any study-related procedure\n\nExclusion Criteria:\n\n* STEMI as the clinical presentation.\n* Uncontrolled or recurrent ventricular tachycardia.\n* Hemodynamic instability.\n* Hemodialysis or peritoneal dialysis.\n* Left main coronary artery stenosis \\> 50%\n* Atrial fibrillation, flutter, or arrhythmias during CT acquisition.\n* Previous PCI in the target vessel or CABG.\n* BMI ≥ 40 kg\u002Fm2\n* Insufficient CT quality assessed by the Core lab.\n* Comorbidity with life expectancy ≤ 2 years.\n* Planned major cardiac or non-cardiac surgery within 24 months after the index procedure Note: Major surgery is any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: Minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.\n* The subject has received a solid organ transplant that is functioning or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.\n* The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.\n* The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest\u002Fmediastinum.\n* Subject has a platelet count \\\u003C100,000 cells\u002Fmm3 or \\>700,000 cells\u002Fmm3.\n* The subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.\n* The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, or any prior intracranial bleed, or any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy \\\u003C2 years for any non-cardiac cause.\n* Subject is currently participating in another investigational drug or device clinical study.\n* Pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.\n* Unable to provide written informed consent (IC).","85 Years",{"count":137,"type":22},700,[25],"The OPTIMAL randomized clinical trial has been designed to compare two imaging strategies and to test the hypothesis that a calcium modification strategy informed by coronary CT angiography (CCTA) will improve procedural efficiency and effectiveness compared with the current standard of care (IVUS-guided PCI) while achieving similar clinical outcomes in patients with hemodynamically significant calcified coronary artery disease.",[30,40,29,31,32,33,39],[142,143],"IVUS","CT","2026-02-09",{"date":146,"type":52},"2026-02-10",{"date":148,"type":52},"2025-12-22",{"date":150,"type":22},"2030-01-01",{"name":152,"class":98},"Fundación EPIC",13,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":161,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100611186","phase-4-beacon-aa-apixaban-with-or-without-clopidogrel-in-stroke-patients-with-atrial-fibrillation-and-cerebral-atherosclerosis-100611186","NCT07237308","BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis","A Multicenter Prospective Randomized Study to Evaluate the Efficacy of Apixaban and Clopidogrel on the Prevention of Recurrent Ischemic Stroke in Patients With Atrial Fibrillation and Cerebral Atherosclerosis","Inclusion Criteria:\n\n1. Adults aged 19 years or older at the time of enrollment.\n2. Patients with non-valvular atrial fibrillation (NVAF) documented by electrocardiography or medical records.\n3. Acute ischemic stroke confirmed by brain MRI (diffusion-weighted and FLAIR sequences), with neurological symptoms occurring within 5 days prior to randomization.\n4. Presence of clinically significant atherosclerosis in the cerebral or aortic arteries, meeting at least one of the following criteria:\n\n   ① ≥30% stenosis in the relevant artery (the artery supplying the infarcted territory) demonstrated by CTA, MRA, or DSA - using the WASID criteria for intracranial arteries and NASCET criteria for extracranial arteries.\n\n   ② High-risk atherosclerotic plaque features in the relevant artery demonstrated by CTA, MRA, or ultrasound, such as ulceration, intraplaque hemorrhage, mobile plaque, or a large lipid core (involving ≥25% of plaque cross-sectional area) on CTA\u002FMRA, or ulceration, mobile plaque, or hypoechoic\u002Fecholucent plaque on ultrasound; or presence of branch artery occlusive disease (BAOD).\n\n   ③ Complex aortic plaque (≥4 mm in thickness, mobile, or ulcerative) identified in the ascending aorta or aortic arch by transthoracic\u002Ftransesophageal echocardiography or coronary CT angiography.\n5. Ability and willingness to provide written informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Presence of mechanical heart valves or rheumatic mitral stenosis.\n2. Requirement for antiplatelet agents other than clopidogrel.\n3. Planned percutaneous coronary intervention, coronary artery bypass graft surgery, carotid endarterectomy, or intracranial stenting within 3 months after enrollment.\n4. Presence of mural thrombus in the heart confirmed by imaging.\n5. Renal impairment with creatinine clearance ≤30 mL\u002Fmin\u002F1.73 m².\n6. Severe hepatic impairment, including acute hepatitis, chronic active hepatitis, hepatic lesions or coagulopathy, hepatic failure, or laboratory evidence of AST\u002FALT \\>2× the upper limit of normal (ULN) or total bilirubin \\>1.5× ULN.\n7. Small-vessel occlusion (lacunar infarction) according to the TOAST classification.\n8. History within the past 30 days of gastrointestinal bleeding, vascular malformation of the brain or spinal cord, recent brain, spinal, or ophthalmologic surgery or trauma, esophageal varices, or intracranial hemorrhage at any time; or chronic regular use of NSAIDs (≥3 days per week for ≥2 consecutive weeks).\n9. Ischemic stroke occurring despite concurrent use of both NOAC and antiplatelet therapy.\n10. Planned surgery or high-bleeding-risk procedure within 3 months, or presence of active bleeding at enrollment.\n11. Anemia (hemoglobin \\\u003C 8.0 g\u002FdL) or thrombocytopenia (platelet count \\\u003C 100,000\u002FµL).\n12. Pre-stroke modified Rankin Scale (mRS) ≥ 2.\n13. Severe comorbid illness or malignancy not in complete remission with an expected life expectancy \\\u003C1 year.\n14. Known hypersensitivity or allergy to apixaban or clopidogrel.\n15. Pregnant or breastfeeding women.\n16. Uncontrolled diabetes mellitus (HbA1c \\> 10.0%) or severe hypertension (systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg).\n17. Concomitant use of strong CYP3A4 and P-glycoprotein inhibitors that can significantly increase apixaban exposure (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin).\n18. Concomitant use of strong CYP2C19 inducers that can reduce clopidogrel antiplatelet effect (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort).\n19. Clinically significant mass effect due to space-occupying cerebral infarction, or patients expected to require decompressive craniectomy, including those with midline shift \\> 5 mm, loss of basal cisterns, herniation, fourth-ventricle compression, or obstructive hydrocephalus in posterior fossa infarcts.\n20. Intracranial hemorrhage or hemorrhagic transformation (PH1 or PH2) according to ECASS criteria.\n21. Participation in another interventional clinical trial within the past 30 days or concurrent participation in another interventional study (non-interventional observational or registry studies may be allowed at the investigator's discretion).\n22. Any other condition that, in the investigator's judgment, would make participation or continued involvement in the study inappropriate or infeasible.","19 Years",{"count":163,"type":22},586,[165],"PHASE4","This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis. Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of symptomatic or asymptomatic recurrent ischemic lesions detected on brain MRI (DWI\u002FFLAIR) at 30 ± 5 days after initiation of study medication.",[168,169,170,171,31],"Stroke","Ischemic","Atrial Fibrillation","Intracrnaial Arterioscelrosis","NOT_YET_RECRUITING","2025-11-14",{"date":175,"type":52},"2025-11-19",{"date":177,"type":22},"2025-12",{"date":179,"type":22},"2029-10",{"name":181,"class":98},"Yonsei University",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":60},"100574105","imaging-of-intracranial-and-extracranial-arterial-atherosclerotic-plaques-using-different-field-strength-mris-100574105","NCT06754956","Imaging of Intracranial and Extracranial Arterial Atherosclerotic Plaques Using Different Field Strength MRIs","Imaging Study of Intracranial and Extracranial Arterial Atherosclerotic Plaques Using 3.0T and 5.0T MRI: A Prospective Self-Controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Moderate to severe intracranial or extracranial arterial stenosis (stenosis degree: 50% to 99%, confirmed by CTA, MRA, or DSA);\n* Written informed consent signed by the patient or their legal representative.\n\nExclusion Criteria:\n\n* Non-atherosclerotic intracranial arterial stenosis, such as dissection or moyamoya disease;\n* Contraindications to MRI, such as claustrophobia or presence of a cardiac pacemaker;\n* Allergy to gadolinium-based contrast agents;\n* Poor MRI image quality preventing analysis;\n* Abnormal liver or kidney function;\n* History of any prior endovascular treatment;\n* Presence of implants posing potential safety risks in 5.0T MRI, such as non-removable metallic dental prostheses, stents, or other metallic implants.","95 Years",{"count":191,"type":22},100,[25],"Atherosclerotic stenosis of the carotid and intracranial arteries is one of the leading causes of ischemic cerebrovascular events worldwide. Among these, intracranial atherosclerotic stenosis has an incidence rate of up to 46.6% in patients with ischemic stroke or transient ischemic attack (TIA) in China. The continuous advancement of high-resolution vascular wall imaging (HR-VWI) technology has enabled multi-dimensional imaging of the arterial walls of both intracranial and extracranial vessels. By suppressing intravascular flow, this technique allows clear visualization of the vascular wall morphology and signal characteristics, as well as the identification of plaque composition and assessment of vulnerable plaque features. However, due to the smaller size of intracranial atherosclerotic plaques, the image quality and effectiveness of current 3.0T high-resolution magnetic resonance imaging (MRI) are influenced by hardware and software limitations, as well as imaging parameters, making it difficult to accurately perform qualitative and quantitative analysis of intracranial and extracranial plaques. The advent of ultra-high field 5.0T MRI overcomes the limitations of 3.0T MRI in imaging, significantly improving the signal-to-noise ratio and allowing for clearer visualization of the signal characteristics of the arteria.",[195,196,31],"High Resolution Vessel Wall Imaging","Intracranial Atherosclerotic Stenosis, ICAS","2025-06-26",{"date":199,"type":52},"2025-06-29",{"date":201,"type":52},"2025-01-10",{"date":203,"type":22},"2027-12-23",{"name":205,"class":98},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":60},"100567636","myocardial-perfusion-quantification-with-spect-using-multi-pinhole-collimator-compared-to-photon-counting-coronary-cta-100567636","NCT06670768","Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTA","Myocardial Perfusion Quantification With Single Photon Emission Computed Tomography Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary Computed Tomography Angiography","MY-FUSION","Inclusion Criteria:\n\n* suspected coronary artery disease\n* referred to coronary CTA or SPECT MPI by the patient's physician\n* agrees to the other imaging modality that was not indicated by their physician (coronary CTA or SPECT MPI)\n* suitable for informed consent\n\nExclusion Criteria:\n\n* moderate or severe aortic valve stenosis\n* atrial fibrillation\n* pregnancy or breastfeeding\n* history of coronary artery bypass graft implantation\n* history of stent implantation\n* chronic renal failure (eGFR \\\u003C 30 ml\u002Fm2)\n* active oncological treatment\n* congenital heart disease\n* left or right bundle branch block",{"count":215,"type":22},50,[25],"This prospective study aims to compare functional abnormalities detected using myocardial perfusion SPECT imaging (MPI SPECT) with the extent and severity of anatomical findings on coronary computed tomography angiography (coronary CTA). Additionally, the investigators aim to enhance the diagnostic value of MPI SPECT by quantifying myocardial blood flow and utilizing myocardial flow reserve calculated from dynamic SPECT images.\n\n50 patients with suspected coronary artery disease are anticipated to be enrolled. Pharmacological stress and rest-phase dynamic and static MPI SPECT following an additional coronary CTA scan are to be performed. The obtained multimodality imaging data (functional and anatomical parameters) are planned to be compared and subjected to statistical analysis. The results of this study are expected to improve risk assessment for patients with moderate cardiovascular risk and enhance the diagnostic performance of MPI SPECT.",[39,76,219,29,30,31,40,28,34],"SPECT",[221,222,223,224,225],"Coronary Artery Disease,","Myocardial Perfusion Imaging","Myocardial Perfusion Imaging Absolute Quantification","Myocardial Flow Reserve","Plaque volume","2025-04-24",{"date":228,"type":52},"2025-04-25",{"date":230,"type":52},"2024-03-06",{"date":232,"type":22},"2026-08-30",{"name":234,"class":98},"Semmelweis University",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":161,"maxAge":4,"enrollmentInfo":242,"targetDuration":244,"studyType":110,"phases":4,"briefSummary":245,"conditions":246,"keywords":250,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":263},"100546438","home-blood-pressure-variability-and-its-link-to-arteriosclerosis-and-metabolic-dysfunction-in-hypertensive-patients-100546438","NCT06394934","Home Blood Pressure Variability and Its Link to Arteriosclerosis and Metabolic Dysfunction in Hypertensive Patients","Impact of Home and Clinical Blood Pressure Variability on Arteriosclerosis and Metabolic Indicators","Inclusion Criteria:\n\n1. Adults aged 19 years or older.\n2. Diagnosed with hypertension.\n3. Regular use of antihypertensive medication for at least two years.\n4. Access to a home blood pressure monitor.\n5. Comprehensive medical records available for the past year.\n\nExclusion Criteria:\n\n1\\. Participants who are unable to consent or who might not reliably use the home monitoring app.",{"count":243,"type":22},4188,"3 Years","This observational study investigates the correlation between home blood pressure variability (BPV) and arteriosclerosis, alongside metabolic indicators, in hypertensive patients over a three-year period. The research specifically focuses on the predictive value of home BPV for major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and heart failure hospitalizations. Utilizing a mobile application called Healthscan for daily BP monitoring, the study aims to enhance the understanding of how BPV impacts cardiovascular and metabolic health in a real-world setting.",[247,248,31,249],"Hypertension","Blood Pressure Monitoring, Home","Metabolic Syndrome X",[251,252,253,31],"Home Blood Pressure Monitoring","Blood Pressure Variability","Pulse Wave Velocity","2024-04-28",{"date":256,"type":52},"2024-05-01",{"date":258,"type":52},"2024-01-09",{"date":260,"type":22},"2029-12-31",{"name":262,"class":98},"Korea University Anam Hospital",2,{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":17,"minAge":272,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":60},"100507242","new-cardiovascular-risk-screening-strategy-100507242","NCT05884840","New Cardiovascular Risk Screening Strategy.","Health Program for prEvention of cardiovascuLar disEases Based on a Risk screeNing Strategy With Ankle-brachial Index.","HELENA","Inclusion Criteria:\n\n* Patients aged 50 to 74, which are free or do not have previous history of CVD. Patients that hold a REGICOR CV risk score ≥7, and REASON risk core ≥7, during a routine primary care visit\n\nExclusion Criteria:\n\n* Symptomatic PAD\n* Coronary disease\n* Stroke\n* Cardiac revascularization","50 Years","74 Years",{"count":275,"type":22},54000,[25],"Mortality due to cardiovascular disease (CVD) in Spain accounted for 29% of all deaths (32% in women and 26% in men) in 2017. Out of those, 67% were related to a coronary or a cerebrovascular disease .\n\nA key strategy in primary prevention of CVD is to use risk functions to individualize preventive interventions for each patient. The current CV risk-screening program in some regions of Spain, is based using an adapted Framingham scale, REGICOR's risk function, which is integrated in the primary care electronic health record. This risk function predicts the probability within 10 years of developing a coronary event. However, this function fails to identify patients that fall into low- or intermediate-risk level, and might develop a CV event in the up following 10 years.\n\nAnkle-brachial index (ABI) is a simple, non-invasive and economic technique, which allows detecting peripheral arterial disease (PAD), and gives independent risk function information compared to other coronary risk functions. Even tough, between 13-27% of middle age population have an ABI ≤ 9, around 50-89% of them do not exhibit any symptoms. However, they hold higher mortality risk and CV events. Current clinical guidelines for PAD screening, have a limited level of evidence, and only recommend using ABI on patients aged 50-70, who have diabetes or are smokers, and patients older than 70 years old.\n\nA new risk function, REASON, to assess CVD risk has been designed. This model has proven to improve predictive capacity of holding an ABI ≤ 0.9 on those patients aged 50-74 that are apparently free of CVD. Therefore, a strategy that combines the current CV risk estimation using REGICOR, and the prediction capacity of pathologic ABI with REASON, would allow detecting high-risk patients with a PAD screening program. It is possible that patients, who hold an ABI ≤ 0.9, even if being asymptomatic, will adopt physician's recommendations on healthy life habits and preventive treatment.\n\nThe aims of this study are:\n\n* To assess the effectiveness and cost-utility of adding a screening program with ABI to the current strategy of CV risk detection to reduce the incidence of CVD and mortality from all causes in the population aged 50 to 74.\n* To assess the effectiveness of adding a screening program with ABI to the current strategy of CV risk detection to improve cardiovascular risk factors in the population aged 50 to 74.",[279,280,113,31,281],"Cardiovascular Prevention","Screening","Asymptomatic","2023-12-22",{"date":284,"type":52},"2023-12-29",{"date":286,"type":52},"2023-11-20",{"date":288,"type":22},"2026-06",{"name":290,"class":98},"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":297,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":300,"conditions":301,"keywords":305,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":60},"100514972","menopause-related-influences-on-leukocyte-distribution-monocyte-function-and-platelet-reactivity-100514972","NCT05985447","Menopause Related Influences on Leukocyte Distribution, Monocyte Function and Platelet Reactivity","Inclusion Criteria:\n\n* Age \\> 18 years\n* Male, female, diverse patients with current treatment in the Department of Cardiology, Pneumology and Angiology.\n* Persons who are able to understand and follow the instructions of the study staff\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Lack of written consent to participate in the study\n* coagulation disorders",true,{"count":299,"type":22},180,"Women and men show marked differences in cardiovascular risk profile and outcome. Women experience fewer cardiovascular events than men before menopause, but this relationship seems to reverse at menopause. These disparities are probably due to hormonal factors, especially the female sex hormone estrogen seems to have a protective influence on the development of atherosclerotic plaques premenopausal.\n\nThe underlying mechanisms of the effect of estrogens on the vessel wall are still insufficiently investigated. In this study, menopause related effects on leukocyte distribution and function as well on platelets and their aggregational response will be evaluated.",[31,302,303,304],"Acute Myocardial Infarction","Cardiovascular Events","Menopause",[306,307,308,309,310,311,312,313,314],"sex","gender","female","male","menopause","hormone replacement therapy","Atherosclerosis","cardiovascular events","cardiovascular risk","2023-08-02",{"date":317,"type":52},"2023-08-14",{"date":319,"type":52},"2022-03-07",{"date":321,"type":22},"2026-12",{"name":323,"class":98},"Heinrich-Heine University, Duesseldorf"]